↓ Skip to main content

New trends in cancer for the 21st century

Overview of attention for book
Cover of 'New trends in cancer for the 21st century'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Prognostic and Therapeutic Targets in the Ewing's Family of Tumors (PROTHETS)
  3. Altmetric Badge
    Chapter 2 Targeted Therapies in Ewing's Sarcoma
  4. Altmetric Badge
    Chapter 3 The CCN3 protein and cancer.
  5. Altmetric Badge
    Chapter 4 EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
  6. Altmetric Badge
    Chapter 5 Molecular Karyotyping in Sarcoma Diagnostics and Research
  7. Altmetric Badge
    Chapter 6 TuBaFrost: European Virtual Tumor Tissue Banking
  8. Altmetric Badge
    Chapter 7 Virtual Microscopy in Virtual Tumor Banking
  9. Altmetric Badge
    Chapter 8 Harmonizing Cancer Control in Europe
  10. Altmetric Badge
    Chapter 9 The Diagnosis of Cancer: “From H&E to Molecular Diagnosis and Back“
  11. Altmetric Badge
    Chapter 10 From Morphological to Molecular Diagnosis of Soft Tissue Tumors
  12. Altmetric Badge
    Chapter 11 Prediction of Response to Neoadjuvant Chemotherapy in Carcinomas of the Upper Gastrointestinal Tract
  13. Altmetric Badge
    Chapter 12 Integrating the Diagnosis of Childhood Malignancies
  14. Altmetric Badge
    Chapter 13 Preclinical Models for Cell Cycle-Targeted Therapies
  15. Altmetric Badge
    Chapter 14 WWOX, a chromosomal fragile site gene and its role in cancer.
  16. Altmetric Badge
    Chapter 15 From Genome to Proteome in Tumor Profiling: Molecular Events in Colorectal Cancer Genesis
  17. Altmetric Badge
    Chapter 16 Effect of Hypoxia on the Tumor Phenotype: The Neuroblastoma and Breast Cancer Models
  18. Altmetric Badge
    Chapter 17 Methylation patterns and chemosensitivity in NSCLC.
  19. Altmetric Badge
    Chapter 18 Pharmacogenomics and Colorectal Cancer
  20. Altmetric Badge
    Chapter 19 Development of pharmacogenomic predictors for preoperative chemotherapy of breast cancer.
  21. Altmetric Badge
    Chapter 20 Vascular Endothelial Growth Factor Inhibitors in Colon Cancer
  22. Altmetric Badge
    Chapter 21 Molecular Imaging of Cancer Using PET and SPECT
  23. Altmetric Badge
    Chapter 22 MRS as Endogenous Molecular Imaging for Brain and Prostate Tumors: FP6 Project “eTUMOR“
  24. Altmetric Badge
    Chapter 23 From Linac to Tomotherapy: New Possibilities for Cure?
  25. Altmetric Badge
    Chapter 24 Targeting mTOR for Cancer Treatment
  26. Altmetric Badge
    Chapter 25 Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.
  27. Altmetric Badge
    Chapter 26 AntiTumor-Associated Antigens IGGS: Dual Positive and Negative Potential Effects for Cancer Therapy
  28. Altmetric Badge
    Chapter 27 Synergistic molecular mechanisms in hormone-sensitive breast cancer.
Attention for Chapter 14: WWOX, a chromosomal fragile site gene and its role in cancer.
Altmetric Badge

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
WWOX, a chromosomal fragile site gene and its role in cancer.
Chapter number 14
Book title
New trends in cancer for the 21st century
Published in
Advances in experimental medicine and biology, December 2006
DOI 10.1007/978-1-4020-5133-3_14
Pubmed ID
Book ISBNs
978-1-4020-4966-8, 978-1-4020-5133-3
Authors

Ramos D, Aldaz CM, Ramos, D., Aldaz, C. M.

Abstract

Allelic imbalances affecting the long arm of chromosome 16 have been extensively reported in the literature as common abnormalities observed in various carcinoma types, As a result of loss of heterozygosity (LOH) studies in breast cancer, we delimited a genomic area within chromosome 16 that demonstrated the highest frequency of abnormalities. This led us to the identification and cloning of WWOX, a candidate tumor suppressor gene (TSG) that spans a fragile region of DNA located at 16q23.3-24.1 (FRA16D: the second most active common chromosomal fragile site in the human genome). This gene encodes a protein that contains two WW domains responsible of protein-protein interactions and a short-chain dehydrogenase (SDR) domain likely involved in sex steroid metabolism. Protein-protein interactions of WWOX with other peptides that act as apoptotic regulators as well as nuclear transcription factors have been described. We and other groups have studied the expression of WWOX in multiple tumor types in hormonally and nonhormonally regulated organs. In these studies, a significant correlation of loss of WWOX protein expression, with sex steroid hormone receptors expression and patient outcome, has been demonstrated. Reinsertion of the WWOX gene in WWOX-deficient tumorigenic cancer cell lines has shown a dramatic decrease of tumor growth in vivo, while inhibition of anchorage independent growth was observed in vitro. Further studies are necessary to elucidate the exact biological role of WWOX as a suppressor of tumor growth.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 20%
Other 1 20%
Student > Master 1 20%
Unknown 2 40%
Readers by discipline Count As %
Agricultural and Biological Sciences 1 20%
Medicine and Dentistry 1 20%
Unknown 3 60%